Hengrui Pharmaceutical announced that the company and its subsidiaries Suzhou Shengdia Biomedical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, involving 5 types of drugs: HRS-2329 tablets, HRS-6093 tablets, injectable SHR-9839, HRS-4642 injection, and adbelizumab injection, and agreed to conduct clinical trials. Among them, the total R&D investment for HRS-2329 tablet-related projects is about 116 million yuan, HRS-6093 tablets are about 61.8 million yuan, SHR-9839 related projects are about 128 million yuan, HRS-4642 injections are about 372 million yuan, and adbelizumab injections are about 1.37 billion yuan.

Zhitongcaijing · 2d ago
Hengrui Pharmaceutical announced that the company and its subsidiaries Suzhou Shengdia Biomedical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, involving 5 types of drugs: HRS-2329 tablets, HRS-6093 tablets, injectable SHR-9839, HRS-4642 injection, and adbelizumab injection, and agreed to conduct clinical trials. Among them, the total R&D investment for HRS-2329 tablet-related projects is about 116 million yuan, HRS-6093 tablets are about 61.8 million yuan, SHR-9839 related projects are about 128 million yuan, HRS-4642 injections are about 372 million yuan, and adbelizumab injections are about 1.37 billion yuan.